Taysha Gene Therapies
TSHA
87 hedge funds and large institutions have $230M invested in Taysha Gene Therapies in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 11 reducing their positions, and 8 closing their positions.
325% more call options, than puts
Call options by funds: $259K | Put options by funds: $61K
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
173% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 11
38% more funds holding
Funds holding: 63 → 87 (+24)
0.09% more ownership
Funds ownership: 69.52% → 69.61% (+0.09%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
44% less capital invested
Capital invested by funds: $411M → $230M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.74M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.58M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
+$4.39M |
| 4 |
EP
Eversept Partners
New York
|
+$4.14M |
| 5 |
BlackRock
New York
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$16.3M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$10.4M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$8.78M |
| 4 |
VA
VR Adviser
New York
|
-$8.04M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.16M |
TSHA Hedge Fund Activity: Q4 2023 in Review
87 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2023, worth a combined $230M — down 44% from $411M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TSHA positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $6.74M. The largest seller was TCG Crossover Management, cutting an estimated $16.3M.
- 87 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2023, up from 63 in Q3 2023.
- Funds reported $230M of Taysha Gene Therapies stock for Q4 2023, down 44% quarter-over-quarter.
- 32 funds opened new Taysha Gene Therapies positions in Q4 2023 and 8 closed out, a net change of +24 holders.
- The largest Taysha Gene Therapies buyer in Q4 2023 was Millennium Management, an estimated $6.74M added.
- The largest Taysha Gene Therapies seller in Q4 2023 was TCG Crossover Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q4 2023.